Pleased to share that Igniters Tech Law has advised Enlila in connection with the acquisition of a 50.1% stake for USD 24 million in Crescenta Biosciences Inc.
Enlila, founded in partnership with Türkiye İş Bankası and Harvard University, which holds a 10% stake in the company promising 39 million USD to the company over 10 years, is an innovative biotechnology company dedicated to targeting metabolism to extend health span and transform the way chronic diseases are approached. By joining Crescenta Biosciences' ecosystem, which spans metabolic disease, age-related conditions, and cancer, Enlila's technology gains access to significantly broader reach.
Congratulations to both teams on this strategic milestone, and we are pleased to have supported the parties throughout the transaction process.